DDInter779 DDInter1676
An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Foscarnet {u} (Compound) binds {v} (Gene) SLC22A6
Foscarnet {u} (Compound) is included by {v} (Pharmacologic Class) DNA Polymerase Inhibitors
Foscarnet {u} (Compound) causes {v} (Side Effect) Blood urea increased
Foscarnet {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Foscarnet {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palonosetron
Foscarnet {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Prednisone
Foscarnet {u} may lead to a major life threatening interaction when taken with {v} Iohexol
Foscarnet {u} may lead to a major life threatening interaction when taken with {v} Anagrelide
Foscarnet (Compound) binds SLC22A6 (Gene)
Foscarnet (Compound) is included by DNA Polymerase Inhibitors (Pharmacologic Class)
Foscarnet (Compound) causes Blood urea increased (Side Effect)
Foscarnet may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Prednisone
Foscarnet may lead to a major life threatening interaction when taken with Iohexol
Foscarnet may lead to a major life threatening interaction when taken with Anagrelide